{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:24:09Z","timestamp":1787617449120,"version":"build-2736575974"},"reference-count":47,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study aimed to describe the characteristics of medication errors involving clonidine in paediatric patients and reported to French Network of Pharmacovigilance and Poison Control Centres.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective observational study analysed clonidine\u2010related medication errors reported between 1985 and June 2024 in patients under 12\u2009years. Data were extracted from both the French Pharmacovigilance and Poison Control Centres databases. Descriptive statistics were applied to identify common patterns and risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 91 cases were analysed. Most errors occurred during the administration stage in hospital settings (73%). Overexposure exceeding 10 times the prescribed dose was the most frequent (52%), often resulting from the erroneous adaptation of adult formulations for paediatric use. Among 87 cases of overexposure, 41 children (47%) received preventive interventions (e.g., activated charcoal) and 63 (72%) experienced clinical manifestations such as bradycardia, hypotension or somnolence. Among them, 20 (32%) received curative treatment such as fluid support (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910; 50%), atropine (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096; 30%) and naloxone (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096; 30%) administration. Challenges in weight\u2010based dosing and the lack of paediatric\u2010specific formulations were identified as significant contributors to errors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Medication errors involving clonidine in paediatric patients are predominantly linked to challenges during hospital administration, exacerbated by the absence of paediatric formulations. Addressing these risks requires regulatory changes, including the development of ready\u2010to\u2010use paediatric formulations and standardized dosing protocols, to enhance clonidine safety in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70797","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:49:49Z","timestamp":1787615389000},"source":"Crossref","is-referenced-by-count":0,"title":["Paediatric clonidine medication errors: Findings from a multicentre French study"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4597-1738","authenticated-orcid":false,"given":"Eve\u2010Marie","family":"Thillard","sequence":"first","affiliation":[{"name":"Department of Pharmacosurveillance, Pharmacovigilance Regional Centre of Centre Val de Loire University Hospital of Tours  Tours France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Facile","sequence":"additional","affiliation":[{"name":"Department of Pharmacotoxicology Hospices Civils de Lyon  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Lepelley","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Regional Centre of Grenoble Grenoble University Hospital  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Cellier","sequence":"additional","affiliation":[{"name":"Department of Pharmacotoxicologie University Hospital of Angers  Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9626-3571","authenticated-orcid":false,"given":"Laurent","family":"Chouchana","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Regional Centre, Pharmacology Department, Cochin Hospital, APHP UMR1343 INSERM Universit\u00e9 Paris Cit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gautier","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Regional Centre of Lille, Pharmacology Department Lille University Hospital  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Azzouz","sequence":"additional","affiliation":[{"name":"Lille Poison Control and Toxicovigilance Centre CHU  Lille France"},{"name":"Univ. Lille, CHU Lille, ULR 2694 \u2013 METRICS  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Vial","sequence":"additional","affiliation":[{"name":"Department of Pharmacotoxicology Hospices Civils de Lyon  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie\u2010Pierre","family":"Jonville\u2010Bera","sequence":"additional","affiliation":[{"name":"Department of Pharmacosurveillance, Pharmacovigilance Regional Centre of Centre Val de Loire University Hospital of Tours  Tours France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010\u20101260"},{"key":"e_1_2_11_3_1","unstructured":"Center for Drug Evaluation and Research.Approval package for KAPVAY. Published online September2010. Accessed January 12 2026.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022331Orig1s001.pdf"},{"key":"e_1_2_11_4_1","unstructured":"EMEA\u2010003198\u2010PIP01\u201322 \u2010 Plan d'investigation p\u00e9diatrique|Agence europ\u00e9enne des m\u00e9dicaments (EMA). June 10 2022. Accessed February 3 2025.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/paediatric-investigation-plans\/emea-003198-pip01-22"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/pch\/pxy114"},{"issue":"3","key":"e_1_2_11_6_1","first-page":"270","article-title":"Clonidine in paediatrics\u2014a review","volume":"53","author":"Basker S","year":"2009","journal-title":"Indian J Anaesth"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14552"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023\u2010065610"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542\u2010199311000\u201000009"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjane.2020.12.003"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2020.04.027"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006565\u2010200208000\u201000014"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.2.471"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03161223"},{"key":"e_1_2_11_15_1","unstructured":"WHO launches global effort to halve medication\u2010related errors in 5 years. Accessed January 20 2025.https:\/\/www.who.int\/news\/item\/29-03-2017-who-launches-global-effort-to-halve-medication-related-errors-in-5-years"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.16.2114"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ambp.2007.04.004"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574884712666170317161935"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.3233\/JRS\u2010200058"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809102501018"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010199920020\u201000002"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246\u2010199010000\u201000014"},{"key":"e_1_2_11_23_1","unstructured":"LOI N\u00b0 2012\u2013300 Du 5 Mars 2012 Relative Aux Recherches Impliquant La Personne Humaine (1).2012."},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16177"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12245\u2010019\u20100231\u20101"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2004.09.027"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.156.4.392"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.3205\/000091"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134\u2010006\u20100190\u2010x"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13312\u2010014\u20100352\u20109"},{"issue":"1","key":"e_1_2_11_31_1","first-page":"85","article-title":"Clonidine versus chloral hydrate for recording sleep EEG in children","volume":"14","author":"Ashrafi MR","year":"2020","journal-title":"Iran J Child Neurol"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460\u20109592.2010.03397.x"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcped.2014.07.014"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2018.1450986"},{"issue":"3","key":"e_1_2_11_35_1","first-page":"220","article-title":"Pediatric clonidine intoxications","volume":"32","author":"Bamshad MJ","year":"1990","journal-title":"Vet Hum Toxicol"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02751449"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098617746053"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010016\u20100463\u20104"},{"key":"e_1_2_11_39_1","unstructured":"Open Medic: base compl\u00e8te sur les d\u00e9penses de m\u00e9dicaments \u2010 2014 \u00e0 2024|L'Assurance Maladie. April 21 2026. Accessed June 29 2026.https:\/\/www.assurance-maladie.ameli.fr\/etudes-et-donnees\/open-medic-base-complete-depenses-medicaments"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjpo\u20102025\u2010004327"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpem.2019.100716"},{"key":"e_1_2_11_42_1","unstructured":"M\u00e9dicaments \u00e0 usage humain|Banque de donn\u00e9es des m\u00e9dicaments. AFMPS (Agence F\u00e9d\u00e9rale des m\u00e9dicaments et des produits de Sant\u00e9). Accessed April 14 2025.https:\/\/basededonneesdesmedicaments.be\/usage-humain"},{"key":"e_1_2_11_43_1","unstructured":"Electronic Medicines Compendium (EMC). UK Medicines and Healthcare Products Regulatory Agency. Accessed April 14 2025.https:\/\/www.medicines.org.uk\/emc"},{"key":"e_1_2_11_44_1","unstructured":"Administration (TGA) TG.Australian Register of Therapeutic Goods (ARTG). Australian Government. December 18 2021. Accessed April 14 2025.https:\/\/www.tga.gov.au\/resources\/artg"},{"key":"e_1_2_11_45_1","unstructured":"Drug Product Database online query.Government of Canada. Accessed April 14 2025.https:\/\/health-products.canada.ca\/dpd-bdpp\/"},{"key":"e_1_2_11_46_1","unstructured":"Revised priority list for studies on off\u2010patent paediatric medicinal products. Eur Med Agency2013;EMA\/PDCO\/98717\/2012. Accessed April 11 2025.https:\/\/www.ema.europa.eu\/en\/documents\/other\/revised-priority-list-studies-patent-paediatric-medicinal-products_en.pdf"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102017\u2010016031"},{"key":"e_1_2_11_48_1","unstructured":"US Food & Drug Administration.Drugs@FDA: FDA\u2010approved drugs. Accessed April 14 2025.https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70797","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70797","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:49:52Z","timestamp":1787615392000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":47,"alternative-id":["10.1002\/bcp.70797"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70797","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"bcp.70797"}}